The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist 1 , 2 Yoo La Lee, 3 and Chang Hee Jung 1 , 2 Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists have been used extensively in the clinic and have an established safety profile in cardiovascular disease settings
The typical adult dosage is 0.25 mL to 2 mL per dose, depending on the severity of the deficiency or the clinical indication

Preparing for your consultation : Before your appointment, document: Your weight history, including previous weight loss attempts and outcomes Current medications and medical conditions Perimenopausal symptoms and their impact on daily life Dietary habits and physical activity levels Family history of obesity, diabetes, or thyroid conditions Specific concerns about weight gain and health goals Questions to discuss with your GP : "Am I eligible for referral to specialist weight management services that might consider GLP-1 medications?" "What are the realistic expectations for weight loss with these treatments?" "How would this medication interact with any HRT or other treatments I'm taking?" "What monitoring would be required during treatment?" "What happens when I stop the medicationwill weight return?" "Are there local NHS weight management services that might help?" "Would addressing my perimenopausal symptoms with HRT potentially help with my overall health?" Setting realistic expectations is crucial

Spicy foods, fatty meals, fried foods, and large evening meals can raise stomach pressure and worsen reflux
Abstract Background Glucagon-like peptide 1 receptor agonists (GLP1RAs) are used in the treatment of diabetes and obesity
The Celebrity Connection: Why Everyone Is Talking About Ozempic When Kelly Clarkson mentioned her weight loss journey, it wasnt just about aesthetics